Athira Pharma Reports Third Quarter 2021 Financial Results and Business Update
10. November 2021 16:05 ET
|
Athira Pharma, Inc.
– Completed enrollment of ACT-AD trial with topline data expected in the first half of 2022; LIFT-AD is actively recruiting with topline data expected by the end of 2022 – – Presented program updates...
Athira Pharma Presents Overview and Update from ACT-AD and LIFT-AD Trials of ATH-1017 in mild-to-moderate Alzheimer’s Disease at CTAD Conference
10. November 2021 11:50 ET
|
Athira Pharma, Inc.
– Balanced baseline characteristics in ACT-AD and LIFT-AD to date –– Topline data from ACT-AD trial targeted for first half of 2022 – BOTHELL, Wash., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Athira...
Athira Pharma to Present at Upcoming Investor Conferences
08. November 2021 07:00 ET
|
Athira Pharma, Inc.
-Stifel 2021 Virtual Healthcare Conference-- Jefferies 2021 London Healthcare Conference- BOTHELL, Wash., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage...
Athira Pharma to Host Educational Webinar on the Clinical Applications of ERP P300
29. Oktober 2021 07:00 ET
|
Athira Pharma, Inc.
Neurologist Dr. John Michael Olichney to discuss utility of P300 to assess cognitive function Webinar to be held Friday, Nov. 5, at 9 a.m. PT / 12 p.m. ET BOTHELL, Wash., Oct. 29, 2021 (GLOBE...
Athira Pharma Announces Completion of Enrollment in Phase 2 ACT-AD Trial Evaluating ATH-1017 for Mild-to-Moderate Alzheimer’s Disease
22. Oktober 2021 08:22 ET
|
Athira Pharma, Inc.
-Topline data targeted for 1H22- BOTHELL, Wash., Oct. 22, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small...
Athira Pharma Announces Leadership Changes; Mark Litton, Ph.D., M.B.A. Named President and Chief Executive Officer; Rachel Lenington, M.B.A. Named Chief Operating Officer
21. Oktober 2021 16:05 ET
|
Athira Pharma, Inc.
Special Committee of the Board of Directors has concluded its investigation of Dr. Leen Kawas’s Doctoral ResearchConference call to be held October 21, 2021 at 4:30 pm ET BOTHELL, Wash., Oct. 21,...
Athira Pharma to Present Updates from Phase 2/3 Trials of ATH-1017 at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
29. September 2021 08:05 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Sept. 29, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal...
Athira Pharma to Present on ERP P300 as a Direct, Functional, Non-Invasive Biomarker at the Annual Biomarkers for Alzheimer’s Disease Summit
23. August 2021 07:30 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Aug. 23, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...
Athira Pharma Reports Second Quarter 2021 Financial Results and Business Update
16. August 2021 16:01 ET
|
Athira Pharma, Inc.
- Initiated open label extension for LIFT-AD and ACT-AD trials of ATH-1017 allowing for an additional six months of treatment - ACT-AD and LIFT-AD are actively recruiting; topline data of...
Athira Pharma Mourns the Loss of Chair of Board of Directors, Tadataka Yamada, M.D.
05. August 2021 16:56 ET
|
Athira Pharma, Inc.
BOTHELL, Wash., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health...